Brief: Natera Announces Enrollment Of First Patients In Sagittarius: A Randomized, Phase III Clinical Trial In Colon Cancer
12/12/2024 13:07
Dec 12 (Reuters) - Natera NTRA.O :
* NATERA ANNOUNCES ENROLLMENT OF FIRST PATIENTS IN
SAGITTARIUS: A
RANDOMIZED, PHASE III CLINICAL TRIAL IN COLON CANCER
* NATERA INC - 700-900 PATIENTS EXPECTED TO BE ENROLLED IN
TRIAL
Source text: ID:nBw8BYsKHa
Further company coverage: NTRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers